Speed and need: twin development challenges in rapid response for a SARS-CoV-2 antibody cocktail

Neutralizing antibodies are one available tool for the treatment of infectious diseases. Speed in developing monoclonal antibody treatments is an understood requirement for emerging infectious diseases, and need for COVID-19 treatments during the worldwide pandemic has provided additional urgency. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Lehman, Aimee, Muñiz, Virginia A., Chaney, Ryan, Pimentel, Joseph, Mattila, John, Lawrence, Shawn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920878/
https://www.ncbi.nlm.nih.gov/pubmed/35447504
http://dx.doi.org/10.1016/j.copbio.2022.102715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920878/
https://www.ncbi.nlm.nih.gov/pubmed/35447504
http://dx.doi.org/10.1016/j.copbio.2022.102715

Ejemplares similares